Pharmacoepidemiology;Farmakoepidemiologi

Ugeskrift for Laeger

Volumn 167, Issue 20, 2005, Pages 2186-2190

  Hallas, Jesper ^a   Sørensen, Henrik Toft ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CIMETIDINE; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; SEROTONIN UPTAKE INHIBITOR;

ACUTE HEART INFARCTION; CANCER RISK; CASE CONTROL STUDY; COLORECTAL ADENOMA; DENMARK; GASTROINTESTINAL HEMORRHAGE; HUMAN; PEPTIC ULCER; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; PROPHYLAXIS; REGISTER; REVIEW; SUDDEN DEATH;

ADVERSE DRUG REACTION REPORTING SYSTEMS; CONFOUNDING FACTORS (EPIDEMIOLOGY); DENMARK; DRUG UTILIZATION; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOEPIDEMIOLOGY; PRESCRIPTIONS, DRUG; REGISTRIES;

EID: 20344385782     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Strom BL. What is pharmacoepidemiology? I: Strom BL, red. Pharmacoepidemiology. 3rd edition. Chichester: Wiley and Sons, 2000:3.
2. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-27.
3. Garcia Rodriguez LA, Hernandez-Diaz S. Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology 2001;12:570-6.
4. De Abajo FJ, Garcia Rodriguez LA, Montero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: a population-based case-control study. BMJ 1999;319:1106-9.
5. Dalton SO, Johansen C, Mellemkjaer L et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch Intern Med 2003;163:59-64.
6. Baron JA, Cole BF, Sandler RS et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003;348:891-9.
7. Sørensen HT, Friis S, Norgard B et al. Risk of cancer in a large cohort of non-aspirin NSAID users: a population-based study. Br J Cancer 2003;88:1687-92.
8. Rockwood K, Darvesh S. The risk of dementia in relation to statins and other lipid lowering agents. Neurol Res 2003;25:601-4.
9. Meier CR, Schlienger RG, Kraenzlin ME et al. HMG-CoA reductase inhibitors and the risk of fractures. JAMA 2000;283:3205-10.
10. Graham DJ, Campen D, Hui R et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005;365:475-81.
11. Douthwaite AH, Lintott GAM. Gastroscopic observation of effect of aspirin and certain other substances on stomach. Lancet 1938;2:1222-5.
12. Levy M. Aspirin use in patients with major upper gastrointestinal bleeding and peptic-ulcer disease. N Engl J Med 1974;290:1158-62.
13. Bright RA, Everitt DE. β-blockers and depression. Evidence against an association. JAMA 1992;267:1783-7.
14. Hallas J. Evidence of depression provoked by cardiovascular medication. Epidemiology 1996;7:478-85.
15. Stahl M, Lindquist M, Edwards IR et al. Introducing triage logic as a new strategy for the detection of signals in the WHO Drug Monitoring Database. Pharmacoepidemiol Drug Saf 2004;13:355-63.
16. Hallas J, Gram LF, Grodum E et al. Drug related hospital admissions in medical wards. Br J Clin Pharmacol 1992;33:61-8.
17. Haramburu F, Moride Y, Begaud B. Temporal trends in spontaneous reporting of unlabelled adverse drug reactions. Br J Clin Pharmacol 1997;43:299-301.
18. Jick H, Vessey MP. Case-control studies in the evaluation of drug-induced illness. Am J Epidemiol 1978;107:1-7.
19. Rothman KJ, Greenland S, red. Modern epidemiology. 2. edition. Philadelphia: Lippincott-Raven, 1998.
20. Boston Collaborative Drug Surveillance Program. Regular aspirin intake and acute myocardial infarction. BMJ 1974;1:440-4.
21. Gudmundsson LS, Johannsson M, Thotgeirsson G et al. Risk profiles and prognosis of treated and untreated hypertensive men and women in a population-based longitudinal study: the Reykjavik Study. J Hum Hypertens 2004; 18:615-22.
22. Wolfe F, Anderson J, Burke TA et al. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy. J Rheumatol 2002;29: 467-73.
23. Miettinen OS. The need for randomization in the study of intended effects. Stat Med 1983;2:267-71.
24. Collet J-P, Boivin J-F. Bias and confounding in pharmacoepidemiology. I: Strom BL. red. Pharmacoepidemiology. 3rd edition. Chicnester: Wiley and Sons, 2000:775-7.
25. Møller H, Lindvig K, Klefter R et al. Cancer occurrence in a cohort of patients treated with cimetidine. Gut 1989;30:1558-62.
26. Beasley R, Pearce N, Crane J et al. Beta-agonists: what is the evidence that their use increases the risk of asthma morbidity and mortality? J Allergy Clin Immunol 1999;104:S18-30.
27. Spitzer WO, Suissa S, Ernst P et al. The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med 1992;326:501-6.
28. Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol 1991;133:144-53.
29. Suissa S. The case-time-control design. Epidemiology 1995;6:248-53.
30. Lee D, Bergman U. Studies of drug utilization, I: Strom BL, red. Pharmacoepidemiology. 3rd edition. Chichester: Wiley and Sons, 2000:463-82.
31. Lunde PK, Baksaas I. Epidemiology of drug utilization - basic concepts and methodology. Acta Med Scand Suppl 1988;721:7-11.
32. Guidelines for ATC classification and DDD assignment. Oslo: WHO Collaborating Centre for Drug Statistics Methodology, 2001.
33. Hallas J, Nissen A. Individualised drug utilization statistics. Eur J Clin Pharmacol 1994;47:367-72.
34. Hallas J, Gaist D, Bjerrum L. The waiting-time distribution for prescription drugs. Epidemiology 1997;8:666-70.
35. Støvring H. New statistical methods for estimation of prevalence, incidence and mortality based on pharmacoepidemiological and other health-related databases. Odense: Syddansk Universitet, Department of Statistics and Demography, 2002.
36. Hallas J. Drug utilization statistics for individual-level data. Pharmacoepidemiol Drug Sat 2005 (i trykken).
37. Gaist D, Sørensen HT, Hallas J. The Danish prescription registers. Dan Med Bull 1997;44:445-8.
38. Shapiro S. The role of automated record linkage in the postmarketing surveillance of drug safety: a critique. Clin Pharmacol Ther 1989;46:371-99.
39. Pedersen AT, Lidegaard O, Kreiner S et al. Hormone replacement therapy and risk of non-fatal stroke. Lancet 1997;350:1277-83.
40. Lidegaard O, Kreiner S. Cerebral thrombosis and oral contraceptives. Contraception 1998;57:303-14.